EP0859600A1 - New technology for wet granulation - Google Patents
New technology for wet granulationInfo
- Publication number
- EP0859600A1 EP0859600A1 EP96934274A EP96934274A EP0859600A1 EP 0859600 A1 EP0859600 A1 EP 0859600A1 EP 96934274 A EP96934274 A EP 96934274A EP 96934274 A EP96934274 A EP 96934274A EP 0859600 A1 EP0859600 A1 EP 0859600A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- active ingredient
- solubility
- electrolyte
- compound
- wet granulation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1682—Processes
- A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
Definitions
- This invention is concerned with a novel method of wet granulation in the manufacture of tablets comprising a large dose of a highly soluble compound as active ingredient.
- the novel method comprises the addition of a second compound having the capability of decreasing solubility of the active ingredient prior to agglomeration.
- the invention is particularly concerned with the novel method wherein the active ingredient is a highly soluble ionic compound.
- the novel method of this invention is a wet granulation of an active ingredient which is a highly soluble compound and is to be inco ⁇ orated in a relatively high concentration in compressed tablets which comprises the addition of a second compound to reduce the solubility of the active ingredient prior to the agglomeration step.
- the solubility of the active ingredient is decreased and a signficant increase in the viscosity of the granulation is adequately suppressed.
- This novel method is particularly useful wherein the active ingredient is ionic and has an aqueous solubility of about 10 to about 500 mg/ml, especially about 135 to about 235 mg/ml of water.
- the second compound added during the novel process is ordinarily a soluble ionic compound that can suppress the solubility of the active ingredient especially an electrolyte having an ion in common with that of the active ingredient.
- the tablet compositions prepared by the novel method of this invention are generally art recognized and employ standard excipients based on their compatibility with one another and with the active ingredient .
- excipients are such as: microcrystalline cellulose, dextrates, calcium phosphates, or pregelatinized starch for their compactibility properties, lactose, mannitol, sorbitol, xylitol, sucrose or glucose because of their water solubility which improves the agglomeration process; hydroxypropyl cellulose, hydroxypropyl methylcellulose, polyvinly pyrrolidone as binders or adhesives; Croscarmelose, crospovidone or sodium starch glycolate as disintegrants; and lastly, magnesium or calcium stearate, stearic acid, sodium stearyl fumarate, or polyethylene glycols as lubricants; and a granulating fluid such as water or ethanol: water mixtures.
- the active agent is dry blended with the excipients, and an aqueous solution of the second compound is atomized onto the blend.
- the blend is then granulated by spraying onto it an aqueous solution of the granulating fluid, which may or may not contain the binder. After drying, the granulation is sized, lubricated with magnesium stearate and then compressed to form the tablet cores.
- the active ingredient in the following Example is identified as montelukast sodium. This name is listed in USAN and is used by T.R. Jones, et al in Can. J. Physiol. Pharmacol.. (1995) 73(2), 191-201. It has the name and absolute structural formula as follows:
- Sodium chloride was dissolved in 540 g of water. Hydroxypropyl cellulose was dissolved in 1485 g of water. The microcrystalline cellulose, montelukast sodium, lactose hydrous and Croscarmellose were added together and blended for 5 minutes. The sodium chloride solution was added over 30 seconds and blended for 30 seconds. The hydroxypropylcellulose solution was sprayed onto the mixture over 1.5 minutes and mixed for 30 seconds. After drying, the granulation was sized and then lubricated by addition of the magnesium stearate. The lubricated blend was then compressed to form tablet cores.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Inorganic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Manufacturing Of Micro-Capsules (AREA)
Abstract
Wet granulation of a highly soluble compound is facilitated by addition of a solubility modulator before the agglomeration step.
Description
TITLE OF THE INVENTION
NEW TECHNOLOGY FOR WET GRANULATION
BACKGROUND OF THE INVENTION Wet granulation is a common procedure in the manufacture of compressed tablets. In the preparation of compressed tablets comprising a high dose of a relatively highly soluble active ingredient it has been necessary either to increase the ultimate tablet size or reduce the drug/excipient ratio to obtain a mixture suitable for agglomeration. Otherwise a significant increase in granulation viscosity and poor flow characteristics results from the formation of a gel.
Now, with the present invention, it has been found that wet granulation of a highly soluble compound is greatly facilitated if a solubility modulator is added to the mixture before agglomeration. By this method the solubility of the active ingredient is adequately suppressed and the problem of high viscosity is eliminated.
SUMMARY OF THE INVENΗON
This invention is concerned with a novel method of wet granulation in the manufacture of tablets comprising a large dose of a highly soluble compound as active ingredient. The novel method comprises the addition of a second compound having the capability of decreasing solubility of the active ingredient prior to agglomeration. The invention is particularly concerned with the novel method wherein the active ingredient is a highly soluble ionic compound.
It is even more concerned with the novel method where the solubility of the active ingredient is reduced by the addition of an electrolyte, especially wherein the electrolyte has an ion in commmon with that of the ionic active ingredient.
DETAILED DESCRIPTION OF THE INVENTION
The novel method of this invention is a wet granulation of an active ingredient which is a highly soluble compound and is to be incoφorated in a relatively high concentration in compressed tablets which comprises the addition of a second compound to reduce the solubility of the active ingredient prior to the agglomeration step. By this procedure the solubility of the active ingredient is decreased and a signficant increase in the viscosity of the granulation is adequately suppressed. This novel method is particularly useful wherein the active ingredient is ionic and has an aqueous solubility of about 10 to about 500 mg/ml, especially about 135 to about 235 mg/ml of water.
The second compound added during the novel process is ordinarily a soluble ionic compound that can suppress the solubility of the active ingredient especially an electrolyte having an ion in common with that of the active ingredient.
The tablet compositions prepared by the novel method of this invention are generally art recognized and employ standard excipients based on their compatibility with one another and with the active ingredient . These excipients are such as: microcrystalline cellulose, dextrates, calcium phosphates, or pregelatinized starch for their compactibility properties, lactose, mannitol, sorbitol, xylitol, sucrose or glucose because of their water solubility which improves the agglomeration process; hydroxypropyl cellulose, hydroxypropyl methylcellulose, polyvinly pyrrolidone as binders or adhesives; Croscarmelose, crospovidone or sodium starch glycolate as disintegrants; and lastly, magnesium or calcium stearate, stearic acid, sodium stearyl fumarate, or polyethylene glycols as lubricants; and a granulating fluid such as water or ethanol: water mixtures. The active agent is dry blended with the excipients, and an aqueous solution of the second compound is atomized onto the blend. The blend is then granulated by spraying onto it an aqueous solution of the granulating fluid, which may or may not contain the binder. After
drying, the granulation is sized, lubricated with magnesium stearate and then compressed to form the tablet cores.
The active ingredient in the following Example is identified as montelukast sodium. This name is listed in USAN and is used by T.R. Jones, et al in Can. J. Physiol. Pharmacol.. (1995) 73(2), 191-201. It has the name and absolute structural formula as follows:
Sodium l-[[[(/?)- -[(£)-2-(7-chloro-2-quinolyl)vinyl]-α-[o-(l-hydroxy- l-methylethyl)phenethyl]benzyllthio]methyl] cyclopropaneacetate.
C35H35ClNθ3SNa
EXAMPLE
TABLET CORE COMPRISING MONTELUKAST SODIUM AS
ACTIVE INGREDIENT
INGREDIENT mg/tab g/batch
1. Montelukast Sodium 51.9 583.9
2. Hydroxypropylcellulose 10.0 112.5
3. Microcrystalline cellulose 200.0 2250.0
4. Lactose hydrous 112.0 1260.0
5. Croscarmellose 12.0 135.0 6. Water 2025.0
7. Magnesium stearate 2.0 22.5
8. Sodium chloride 12.0 135.0
Sodium chloride was dissolved in 540 g of water. Hydroxypropyl cellulose was dissolved in 1485 g of water. The microcrystalline cellulose, montelukast sodium, lactose hydrous and Croscarmellose were added together and blended for 5 minutes. The sodium chloride solution was added over 30 seconds and blended for 30 seconds. The hydroxypropylcellulose solution was sprayed onto the mixture over 1.5 minutes and mixed for 30 seconds. After drying, the granulation was sized and then lubricated by addition of the magnesium stearate. The lubricated blend was then compressed to form tablet cores.
Following the above directions but using amounts of active ingredient from about 20 to 200 mg/tablet in place of the 51.9 mg/tablet in the above Example similar results are obtained.
Claims
1. A method for the wet granulation of a highly soluble active ingredient comprising the addition of a second compound as a solubility modulator to decrease the solubility of the active ingredient prior to the agglomeration step of the granulation procedure in the manufacture of compressed tablets comprising about 20-200 mg of active ingredient per tablet.
2. The method of Claim 1 wherein the active ingredient has a solubility of about 10 to 500 mg/ml of water.
3. The method of Claim 2 wherein the solubility of the active ingredient is about 135 to 235 mg/ml of water.
4. The method of Claim 3, wherein the active ingredient is montelukast sodium.
5. The method of Claim 1, wherein the active ingredient is ionic and the second compound is an electrolyte.
6. The method of Claim 5 wherein the electrolyte has an ion in common with the active ingredient.
7. The method of Claim 6, wherein the active ingredient is montelukast sodium.
8. The method of Claim 2, wherein the active ingredient is ionic and the second compound is an electrolyte.
9. The method of Claim 8 wherein the electrolyte has an ion in common with the active ingredient.
10. The method of Claim 9 wherein the active ingredient is montelukast sodium.
11. The method of Claim 3, wherein the active ingredient is ionic and the second compound is an electrolyte.
12. The method of Claim 11, wherein the electrolyte has an ion in common with the active ingredient.
13. The method of Claim 12 wherein the active ingredient is montelukast sodium.
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US616195P | 1995-11-02 | 1995-11-02 | |
| US6161P | 1995-11-02 | ||
| GB9604277 | 1996-02-29 | ||
| GBGB9604277.5A GB9604277D0 (en) | 1996-02-29 | 1996-02-29 | New technology for wet granulation |
| PCT/CA1996/000724 WO1997016173A1 (en) | 1995-11-02 | 1996-10-31 | New technology for wet granulation |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| EP0859600A1 true EP0859600A1 (en) | 1998-08-26 |
Family
ID=26308826
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EP96934274A Ceased EP0859600A1 (en) | 1995-11-02 | 1996-10-31 | New technology for wet granulation |
Country Status (5)
| Country | Link |
|---|---|
| EP (1) | EP0859600A1 (en) |
| JP (1) | JPH11514382A (en) |
| AU (1) | AU709301B2 (en) |
| CA (1) | CA2236175A1 (en) |
| WO (1) | WO1997016173A1 (en) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MY148466A (en) * | 2001-10-26 | 2013-04-30 | Merck Frosst Canada Ltd | Granule formulation |
| CZ298224B6 (en) * | 2003-04-29 | 2007-07-25 | Pliva Istrazivanje I Razvoj D.O.O. | Pharmaceutical composition containing ribavirin as active substance and process for its preparation |
| SI1976522T2 (en) | 2005-12-30 | 2019-11-29 | Krka Tovarna Zdravil D D Novo Mesto | Pharmaceutical composition containing montelukast |
| KR101278572B1 (en) * | 2011-10-18 | 2013-06-25 | 주식회사 네비팜 | Pharmaceutical combinations of leukotriene antagonist and epinastine and their preparing methods |
| WO2014012954A1 (en) | 2012-07-18 | 2014-01-23 | Takeda Gmbh | Treatment of partly controlled or uncontrolled severe asthma |
| CA2936332A1 (en) | 2014-01-22 | 2015-07-30 | Takeda Gmbh | Treatment of partly controlled or uncontrolled severe asthma with a pde4 inhibitor (and in combination with a leukotriene modifier) |
| EP2949321A1 (en) | 2014-05-26 | 2015-12-02 | Sanovel Ilac Sanayi ve Ticaret A.S. | Multilayer formulations of fexofenadine and montelukast |
| WO2017182644A1 (en) | 2016-04-22 | 2017-10-26 | Sanovel Ilac Sanayi Ve Ticaret A.S. | Tablet formulations of montelukast sodium and rupatadine fumarate |
| WO2017182641A1 (en) | 2016-04-22 | 2017-10-26 | Sanovel Ilac Sanayi Ve Ticaret A.S. | Bilayer tablet formulations of montelukast and rupatadine |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5350584A (en) * | 1992-06-26 | 1994-09-27 | Merck & Co., Inc. | Spheronization process using charged resins |
-
1996
- 1996-10-31 AU AU72741/96A patent/AU709301B2/en not_active Ceased
- 1996-10-31 CA CA 2236175 patent/CA2236175A1/en not_active Abandoned
- 1996-10-31 EP EP96934274A patent/EP0859600A1/en not_active Ceased
- 1996-10-31 JP JP9516946A patent/JPH11514382A/en not_active Withdrawn
- 1996-10-31 WO PCT/CA1996/000724 patent/WO1997016173A1/en not_active Application Discontinuation
Non-Patent Citations (1)
| Title |
|---|
| See references of WO9716173A1 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CA2236175A1 (en) | 1997-05-09 |
| AU7274196A (en) | 1997-05-22 |
| AU709301B2 (en) | 1999-08-26 |
| WO1997016173A1 (en) | 1997-05-09 |
| JPH11514382A (en) | 1999-12-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP0814782B1 (en) | Pharmaceutical composition stabilized with a basic agent | |
| FI96274B (en) | The method prepares oral dosage forms of pimobendan | |
| JPH0768125B2 (en) | Oral formulation of acid labile compounds | |
| US20080102120A1 (en) | Solid Pharmaceutical Composition Comprising Valsartan | |
| CA1273877A (en) | Substantially dry tablet formulation for quinoline carboxylic acid antibacterial agents | |
| NZ227032A (en) | Stabilised ace inhibitors, a process for their preparation and stable pharmaceutical compositions therefrom | |
| EP1004305A1 (en) | Stabilized compositions containing benzimidazole-type compounds | |
| US7220762B1 (en) | Methods for stabilizing benzimidazole compounds | |
| CA2083683C (en) | Stable formulation of analapril salt, a process for the preparation thereof and the use thereof | |
| CN113939289A (en) | Oral solid tablet containing Bruton's tyrosine kinase inhibitor and preparation method thereof | |
| JP4127740B2 (en) | Stabilized benzimidazole compound-containing composition | |
| AU709301B2 (en) | New technology for wet granulation | |
| JP4709379B2 (en) | Pharmaceutical formulation containing levothyroxine sodium | |
| EP1976522B1 (en) | Pharmaceutical composition containing montelukast | |
| JP2002520296A (en) | Drug levothyroxine preparation | |
| AU621706B2 (en) | Stabilizing system for solid dosage forms | |
| RU2199318C2 (en) | Silanzetron pharmaceutical medicinal forms stabilized in regard to racemization | |
| EP0952823B1 (en) | Stabilized pharmaceutical compositions and process for the preparation thereof | |
| ZA200308594B (en) | Granular preparations of a gaboxadol. | |
| JPH08325145A (en) | Stable isopropylantipyrine-containing preparation | |
| JP2001270827A (en) | Benzimidazole compound-containing tablet | |
| CN112057427A (en) | Oral solid tablet containing Bruton's tyrosine kinase inhibitor and preparation method thereof | |
| GB2372702A (en) | Stable fosinopril sodium tablet formulation | |
| US20090220552A1 (en) | Formulations containing pantoprazole free acid and its salts | |
| RU2287328C2 (en) | Solid preparation of high absorption |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
| 17P | Request for examination filed |
Effective date: 19980602 |
|
| AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI LU NL PT SE |
|
| RAP1 | Party data changed (applicant data changed or rights of an application transferred) |
Owner name: MERCK FROSST CANADA & CO. |
|
| GRAG | Despatch of communication of intention to grant |
Free format text: ORIGINAL CODE: EPIDOS AGRA |
|
| 17Q | First examination report despatched |
Effective date: 20010205 |
|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION HAS BEEN REFUSED |
|
| 18R | Application refused |
Effective date: 20010820 |